Diagnostic Tips from a Video Series and Literature Review of Patients with Late-Onset Tay-Sachs Disease

Giulietta Maria Riboldi; Heather Lau

doi:10.5334/tohm.726

Abstract

Background: Late-Onset Tay-Sachs (LOTS) disease is a rare, progressive neurological condition that can dramatically affect the life of these patients. The diagnosis of LOTS is easily missed because of the multifaced presentation of these patients, who can initially be assessed by neuromuscular or movement disorder specialists, or psychiatrists. Clinical trials are now becoming available for LOTS. Therefore, early diagnosis can be detrimental for these patients and for insuring informative research outcomes.

Methods: We characterized a cohort of nine patients with LOTS through a detailed clinical and video description. We then reviewed the available literature regarding the clinical description of patients with LOTS. Our findings were summarized based on the predominant phenotype of presentation to highlight diagnostic clues to guide the diagnosis of LOTS for different neurology specialists (neuromuscular, movement disorders) and psychiatrist.

Results: We described a cohort of 9 new patients with LOTS seen at our clinic. Our literature review identified 76 patients mainly presenting with a neuromuscular, cerebellar, psychiatric, stuttering, or movement disorder phenotype. Diagnostic tips, such as the triceps sign, distinct speech patterns, early psychiatric presentation and impulsivity, as well as neurological symptoms (cerebellar or neuromuscular) in patients with a prominent psychiatric presentation, are described.

Discussion: Specific diagnostics clues can help neurologists and psychiatrists in the early diagnosis of LOTS disease. Our work also represent the first video presentation of a cohort of patients with LOTS that can help different specialists to familiarize with these features and improve diagnostic outcomes.

Highlights

Late-Onset Tay-Sachs (LOTS) disease, a severe progressive neurological condition, has multifaced presentations causing diagnostic delays that can significantly affect research outcomes now that clinical trials are available. We highlight useful diagnostic clues from our cohort (including the first video representation of a LOTS cohort) and comprehensive literature review.

References

1Sachs B, Strauss I. THE CELL CHANGES IN AMAUROTIC FAMILY IDIOCY. J Exp Med. 1910 Sep 1; 12(5): 685–95. DOI: 10.1084/jem.12.5.685
Back to article
2Friedland J, Schneck L, Saifer A, Pourfar M, Volk BW. Identification of Tay-Sachs disease carriers by acrylamide gel electrophoresis. Clin Chim Acta. 1970 Jun; 28(3): 397–402. DOI: 10.1016/0009-8981(70)90064-1
Back to article
3Arpaia E, Dumbrille-Ross A, Maler T, Neote K, Tropak M, Troxel C, et al. Identification of an altered splice site in Ashkenazi Tay-Sachs disease. Nature. 1988 May 5; 333(6168): 85–6. DOI: 10.1038/333085a0
Back to article
4Korneluk RG, Mahuran DJ, Neote K, Klavins MH, O’Dowd BF, Tropak M, et al. Isolation of cDNA clones coding for the alpha-subunit of human beta-hexosaminidase. Extensive homology between the alpha- and beta-subunits and studies on Tay-Sachs disease. J Biol Chem. 1986 Jun 25; 261(18): 8407–13. DOI: 10.1016/S0021-9258(19)83927-3
Back to article
5Navon R, Padeh B, Adam A. Apparent deficiency of hexosaminidase A in healthy members of a family with Tay-Sachs disease. Am J Hum Genet. 1973 May; 25(3): 287–93.
Back to article
6Charrow J, Inui K, Wenger DA. Late onset GM₂ gangliosidosis: an alpha-locus genetic compound with near normal hexosaminidase activity. Clin Genet. 1985 Jan; 27(1): 78–84. DOI: 10.1111/j.1399-0004.1985.tb00188.x
Back to article
7Taniike M, Yamanaka S, Proia RL, Langaman C, Bone-Turrentine T, Suzuki K. Neuropathology of mice with targeted disruption of Hexa gene, a model of Tay-Sachs disease. Acta Neuropathol. 1995; 89(4): 296–304. DOI: 10.1007/BF00309622
Back to article
8Stenson PD, Mort M, Ball EV, Shaw K, Phillips A, Cooper DN. The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum Genet. 2014 Jan; 133(1): 1–9. DOI: 10.1007/s00439-013-1358-4
Back to article
9Maegawa GHB, Stockley T, Tropak M, Banwell B, Blaser S, Kok F, et al. The natural history of juvenile or subacute GM₂ gangliosidosis: 21 new cases and literature review of 134 previously reported. Pediatrics. 2006 Nov; 118(5): e1550–1562. DOI: 10.1542/peds.2006-0588
Back to article
10Gross SJ, Pletcher BA, Monaghan KG, Professional Practice and Guidelines Committee. Carrier screening in individuals of Ashkenazi Jewish descent. Genet Med. 2008 Jan; 10(1): 54–6. DOI: 10.1097/GIM.0b013e31815f247c
Back to article
11Neudorfer O, Pastores GM, Zeng BJ, Gianutsos J, Zaroff CM, Kolodny EH. Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients. Genet Med. 2005 Feb; 7(2): 119–23. DOI: 10.1097/01.GIM.0000154300.84107.75
Back to article
12Solovyeva VV, Shaimardanova AA, Chulpanova DS, Kitaeva KV, Chakrabarti L, Rizvanov AA. New Approaches to Tay-Sachs Disease Therapy. Front Physiol. 2018; 9: 1663. DOI: 10.3389/fphys.2018.01663
Back to article
13Barritt AW, Anderson SJ, Leigh PN, Ridha BH. Late-onset Tay-Sachs disease. Pract Neurol. 2017 Oct; 17(5): 396–9. DOI: 10.1136/practneurol-2017-001665
Back to article
14Godeiro-Junior C, Felicio AC, Benites V, Chieia MA, Oliveira ASB. Late-onset hexosaminidase A deficiency mimicking primary lateral sclerosis. Arq Neuropsiquiatr. 2009 Mar; 67(1): 105–6. DOI: 10.1590/S0004-282X2009000100024
Back to article
15Johnson WG, Wigger HJ, Karp HR, Glaubiger LM, Rowland LP. Juvenile spinal muscular atrophy: a new hexosaminidase deficiency phenotype. Ann Neurol. 1982 Jan; 11(1): 11–6. DOI: 10.1002/ana.410110103
Back to article
16Karni A, Navon R, Sadeh M. Hexosaminidase A deficiency manifesting as spinal muscular atrophy of late onset. Ann Neurol. 1988 Sep; 24(3): 451–3. DOI: 10.1002/ana.410240316
Back to article
17Hund E, Grau A, Fogel W, Forsting M, Cantz M, Kustermann-Kuhn B, et al. Progressive cerebellar ataxia, proximal neurogenic weakness and ocular motor disturbances: hexosaminidase A deficiency with late clinical onset in four siblings. J Neurol Sci. 1997 Jan; 145(1): 25–31. DOI: 10.1016/S0022-510X(96)00233-X
Back to article
18Mitsumoto H, Sliman RJ, Schafer IA, Sternick CS, Kaufman B, Wilbourn A, et al. Motor neuron disease and adult hexosaminidase A deficiency in two families: evidence for multisystem degeneration. Ann Neurol. 1985 Apr; 17(4): 378–85. DOI: 10.1002/ana.410170413
Back to article
19Deik A, Saunders-Pullman R. Atypical presentation of late-onset Tay-Sachs disease. Muscle Nerve. 2014 May; 49(5): 768–71. DOI: 10.1002/mus.24146
Back to article
20Peters AS, Markovic K, Schramm A, Schwab S, Heuss D. Late onset hexosaminidase A deficiency in a young adult. Eur J Neurol. 2008 Jul; 15(7): e70–71; author reply e72–73. DOI: 10.1111/j.1468-1331.2008.02170.x
Back to article
21Jamrozik Z, Lugowska A, Gołębiowski M, Królicki L, Mączewska J, Kuźma-Kozakiewicz M. Late onset GM₂ gangliosidosis mimicking spinal muscular atrophy. Gene. 2013 Sep 25; 527(2): 679–82. DOI: 10.1016/j.gene.2013.06.030
Back to article
22Renshaw PF, Stern TA, Welch C, Schouten R, Kolodny EH. Electroconvulsive therapy treatment of depression in a patient with adult GM₂ gangliosidosis. Ann Neurol. 1992 Mar; 31(3): 342–4. DOI: 10.1002/ana.410310320
Back to article
23Navon R, Argov Z, Frisch A. Hexosaminidase A deficiency in adults. Am J Med Genet. 1986 May; 24(1): 179–96. DOI: 10.1002/ajmg.1320240123
Back to article
24Parnes S, Karpati G, Carpenter S, Kin NM, Wolfe LS, Suranyi L. Hexosaminidase-A deficiency presenting as atypical juvenile-onset spinal muscular atrophy. Arch Neurol. 1985 Dec; 42(12): 1176–80. DOI: 10.1001/archneur.1985.04060110058016
Back to article
25Argov Z, Navon R. Clinical and genetic variations in the syndrome of adult GM₂ gangliosidosis resulting from hexosaminidase A deficiency. Ann Neurol. 1984 Jul; 16(1): 14–20. DOI: 10.1002/ana.410160105
Back to article
26Kaback MM. Screening for reproductive counseling: social, ethical, and medicolegal issues in the Tay-Sachs disease experience. Prog Clin Biol Res. 1982; 103 Pt B: 447–59.
Back to article
27Rozenberg R, Pereira L da V. The frequency of Tay-Sachs disease causing mutations in the Brazilian Jewish population justifies a carrier screening program. Sao Paulo Med J. 2001 Jul 5; 119(4): 146–9. DOI: 10.1590/S1516-31802001000400007
Back to article
28Jahnová H, Poupětová H, Jirečková J, Vlášková H, Košťálová E, Mazanec R, et al. Amyotrophy, cerebellar impairment and psychiatric disease are the main symptoms in a cohort of 14 Czech patients with the late-onset form of Tay-Sachs disease. J Neurol. 2019 Aug; 266(8): 1953–9. DOI: 10.1007/s00415-019-09364-3
Back to article
29Gudesblatt M, Ludman MD, Cohen JA, Desnick RJ, Chester S, Grabowski GA, et al. Hexosaminidase A activity and amyotrophic lateral sclerosis. Muscle Nerve. 1988 Mar; 11(3): 227–30. DOI: 10.1002/mus.880110307
Back to article
30Michelakakis H, Papadimitriou A, Divaris R, Mavridou I, Dimitriou E. Plasma lysosomal enzyme levels in patients with motor neuron disease. J Inherit Metab Dis. 1995; 18(1): 72–4. DOI: 10.1007/BF00711376
Back to article
31Drory VE, Birnbaum M, Peleg L, Goldman B, Korczyn AD. Hexosaminidase A deficiency is an uncommon cause of a syndrome mimicking amyotrophic lateral sclerosis. Muscle Nerve. 2003 Jul; 28(1): 109–12. DOI: 10.1002/mus.10371
Back to article
32MacQueen GM, Rosebush PI, Mazurek MF. Neuropsychiatric aspects of the adult variant of Tay-Sachs disease. J Neuropsychiatry Clin Neurosci. 1998; 10(1): 10–9. DOI: 10.1176/jnp.10.1.10
Back to article
33Saleh O. Late Onset Tay-Sachs Disease Presenting as a Brief Psychotic Disorder with Catatonia: A Case Report and Review of the Literature. Jefferson Journal of Psychiatry: [Internet]. 15(1, Article 4). Available from: https://jdc.jefferson.edu/jeffjpsychiatry/vol15/iss1/4. DOI: 10.29046/JJP.015.1.006
Back to article
34Johnson WG. The clinical spectrum of hexosaminidase deficiency diseases. Neurology. 1981 Nov; 31(11): 1453–6. DOI: 10.1212/WNL.31.11.1453
Back to article
35Hurowitz GI, Silver JM, Brin MF, Williams DT, Johnson WG. Neuropsychiatric aspects of adult-onset Tay-Sachs disease: two case reports with several new findings. J Neuropsychiatry Clin Neurosci. 1993; 5(1): 30–6. DOI: 10.1176/jnp.5.1.30
Back to article
36Stendel C, Gallenmüller C, Peters K, Bürger F, Gramer G, Biskup S, et al. Paranoid delusion as lead symptom in two siblings with late-onset Tay-Sachs disease and a novel mutation in the HEXA gene. J Neurol. 2015; 262(4): 1072–3. DOI: 10.1007/s00415-015-7729-0
Back to article
37Barone R, Sturiale L, Fiumara A, Palmigiano A, Bua RO, Rizzo R, et al. CSF N-glycan profile reveals sialylation deficiency in a patient with GM₂ gangliosidosis presenting as childhood disintegrative disorder. Autism Res. 2016 Apr; 9(4): 423–8. DOI: 10.1002/aur.1541
Back to article
38Navon R, Proia RL. The mutations in Ashkenazi Jews with adult GM₂ gangliosidosis, the adult form of Tay-Sachs disease. Science. 1989 Mar 17; 243(4897): 1471–4. DOI: 10.1126/science.2522679
Back to article
39Lichtenberg P, Navon R, Wertman E, Dasberg H, Lerer B. Post-partum psychosis in adult GM₂ gangliosidosis. A case report. Br J Psychiatry. 1988 Sep; 153: 387–9. DOI: 10.1192/bjp.153.3.387
Back to article
40Willner JP, Grabowski GA, Gordon RE, Bender AN, Desnick RJ. Chronic GM₂ gangliosidosis masquerading as atypical Friedreich ataxia: clinical, morphologic, and biochemical studies of nine cases. Neurology. 1981 Jul; 31(7): 787–98. DOI: 10.1212/WNL.31.7.787
Back to article
41Rapin I, Suzuki K, Suzuki K, Valsamis MP. Adult (chronic) GM₂ gangliosidosis. Atypical spinocerebellar degeneration in a Jewish sibship. Arch Neurol. 1976 Feb; 33(2): 120–30. DOI: 10.1001/archneur.1976.00500020048008
Back to article
42Steiner KM, Brenck J, Goericke S, Timmann D. Cerebellar atrophy and muscle weakness: late-onset Tay-Sachs disease outside Jewish populations. BMJ Case Rep. 2016 Mar 31; 2016: bcr2016214634. DOI: 10.1136/bcr-2016-214634
Back to article
43Shapiro BE, Pastores GM, Gianutsos J, Luzy C, Kolodny EH. Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment. Genet Med. 2009 Jun; 11(6): 425–33. DOI: 10.1097/GIM.0b013e3181a1b5c5
Back to article
44Grim KK, Phillips GD, Renner DR. Dysarthria and Stutter as Presenting Symptoms of Late-Onset Tay-Sachs Disease in Three Siblings. Mov Disord Clin Pract. 2015 Sep; 2(3): 289–90. DOI: 10.1002/mdc3.12194
Back to article
45Rucker JC, Shapiro BE, Han YH, Kumar AN, Garbutt S, Keller EL, et al. Neuro-ophthalmology of late-onset Tay-Sachs disease (LOTS). Neurology. 2004 Nov 23; 63(10): 1918–26. DOI: 10.1212/01.WNL.0000144275.76658.F4
Back to article
46De Gasperi R, Gama Sosa MA, Battistini S, Yeretsian J, Raghavan S, Zelnik N, et al. Late-onset GM₂ gangliosidosis: Ashkenazi Jewish family with an exon 5 mutation (Tyr180-–>His) in the Hex A alpha-chain gene. Neurology. 1996 Aug; 47(2): 547–52. DOI: 10.1212/WNL.47.2.547
Back to article
47Harding AE, Young EP, Schon F. Adult onset supranuclear ophthalmoplegia, cerebellar ataxia, and neurogenic proximal muscle weakness in a brother and sister: another hexosaminidase A deficiency syndrome. J Neurol Neurosurg Psychiatry. 1987 Jun; 50(6): 687–90. DOI: 10.1136/jnnp.50.6.687
Back to article
48Barnes D, Misra VP, Young EP, Thomas PK, Harding AE. An adult onset hexosaminidase A deficiency syndrome with sensory neuropathy and internuclear ophthalmoplegia. J Neurol Neurosurg Psychiatry. 1991 Dec; 54(12): 1112–3. DOI: 10.1136/jnnp.54.12.1112
Back to article
49Oates CE, Bosch EP, Hart MN. Movement disorders associated with chronic GM₂ gangliosidosis. Case report and review of the literature. Eur Neurol. 1986; 25(2): 154–9. DOI: 10.1159/000116100
Back to article
50Shapiro BE, Logigian EL, Kolodny EH, Pastores GM. Late-onset Tay-Sachs disease: the spectrum of peripheral neuropathy in 30 affected patients. Muscle Nerve. 2008 Aug; 38(2): 1012–5. DOI: 10.1002/mus.21061
Back to article
51Inzelberg R, Korczyn AD. Parkinsonism in adult-onset GM₂ gangliosidosis. Mov Disord. 1994 May; 9(3): 375–7. DOI: 10.1002/mds.870090325
Back to article
52Jellinger K, Anzil AP, Seemann D, Bernheimer H. Adult GM₂ gangliosidosis masquerading as slowly progressive muscular atrophy: motor neuron disease phenotype. Clin Neuropathol. 1982; 1(1): 31–44.
Back to article
53Rapin I. Myoclonus in neuronal storage and Lafora diseases. Adv Neurol. 1986; 43: 65–85.
Back to article
54Rubin M, Karpati G, Wolfe LS, Carpenter S, Klavins MH, Mahuran DJ. Adult onset motor neuronopathy in the juvenile type of hexosaminidase A and B deficiency. J Neurol Sci. 1988 Oct; 87(1): 103–19. DOI: 10.1016/0022-510X(88)90058-5
Back to article
55Mahuran DJ. Biochemical consequences of mutations causing the GM₂ gangliosidoses. Biochim Biophys Acta. 1999 Oct 8; 1455(2–3): 105–38. DOI: 10.1016/S0925-4439(99)00074-5
Back to article
56Platt FM, d’Azzo A, Davidson BL, Neufeld EF, Tifft CJ. Lysosomal storage diseases. Nat Rev Dis Primers. 2018 Oct 1; 4(1): 27. DOI: 10.1038/s41572-018-0025-4
Back to article

Diagnostic Tips from a Video Series and Literature Review of Patients with Late-Onset Tay-Sachs Disease

Abstract

Paradigm

My account